➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Medtronic
McKinsey
AstraZeneca
Baxter

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,129,431

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,129,431 protect, and when does it expire?

Patent 8,129,431 protects PROLENSA and is included in one NDA.

This patent has nineteen patent family members in thirteen countries.

Summary for Patent: 8,129,431
Title:Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
Inventor(s): Sawa; Shirou (Kobe, JP), Fujita; Shuhei (Kakogawa, JP)
Assignee: Senju Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:10/525,006
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,129,431
Patent Claim Types:
see list of patent claims
Compound; Formulation;

Drugs Protected by US Patent 8,129,431

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb PROLENSA bromfenac sodium SOLUTION/DROPS;OPHTHALMIC 203168-001 Apr 5, 2013 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,129,431

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2003-12427Jan 21, 2003
PCT Information
PCT FiledJanuary 16, 2004PCT Application Number:PCT/JP2004/000350
PCT Publication Date:May 08, 2004PCT Publication Number: WO2004/064828

International Family Members for US Patent 8,129,431

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 393627   Start Trial
Canada 2944832   Start Trial
Canada 3043910   Start Trial
China 100341498   Start Trial
China 1700913   Start Trial
Germany 122011100019   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Boehringer Ingelheim
Merck
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.